Clinical trial
Bifeprunox in the Treatment of Schizophrenia
NCT00193687 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00193687 |
|---|---|
| Title | Bifeprunox in the Treatment of Schizophrenia |
| Official title | An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001) |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | bifeprunox |
| Enrollment | 986 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 24, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: